Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic ...

The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

Guanfacine belongs to the class of medications known as central alpha 2A-adrenergic receptor agonists ... For Intuniv, your child can often be given a 1-milligram (mg) dose once daily.

It acts through agonist effects on the alpha-2 adrenergic system at both the spinal and supraspinal levels to reduce spasm. Peak plasma levels occur 1 hour after oral administration, with a half ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

If patients did not meet the BP goal with the maximum tolerated dose of the initial medication, an open-label step 2 agent (atenolol, 25-100 mg/day; reserpine, 0.05-0.2 mg/day; or clonidine, 0.1-0 ...

BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes ...

Alibaba Group Holding Limited, through its subsidiaries, provides technology infrastructure and marketing reach to help merchants, brands, retailers, and other businesses to engage with their ...